BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Buñay J, Fouache A, Trousson A, de Joussineau C, Bouchareb E, Zhu Z, Kocer A, Morel L, Baron S, Lobaccaro JA. Screening for liver X receptor modulators: Where are we and for what use? Br J Pharmacol 2021;178:3277-93. [PMID: 33080050 DOI: 10.1111/bph.15286] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
Number Citing Articles
1 Kostidis S, Sánchez-López E, Giera M. Lipidomics analysis in drug discovery and development. Curr Opin Chem Biol 2023;72:102256. [PMID: 36586190 DOI: 10.1016/j.cbpa.2022.102256] [Reference Citation Analysis]
2 Zhou QQ, Xiao HT, Yang F, Wang YD, Li P, Zheng ZG. Advancing targeted protein degradation for metabolic diseases therapy. Pharmacol Res 2022;188:106627. [PMID: 36566001 DOI: 10.1016/j.phrs.2022.106627] [Reference Citation Analysis]
3 Sellami A, Réau M, Montes M, Lagarde N. Review of in silico studies dedicated to the nuclear receptor family: Therapeutic prospects and toxicological concerns. Front Endocrinol 2022;13:986016. [DOI: 10.3389/fendo.2022.986016] [Reference Citation Analysis]
4 Deshwal S, Baidya AT, Kumar R, Sandhir R. Structure-based virtual screening for identification of potential non-steroidal LXR modulators against neurodegenerative conditions. J Steroid Biochem Mol Biol 2022;:106150. [PMID: 35787453 DOI: 10.1016/j.jsbmb.2022.106150] [Reference Citation Analysis]
5 Griffett K, Hayes M, Bedia-Diaz G, Appourchaux K, Sanders R, Boeckman MP, Koelblen T, Zhang J, Schulman IG, Elgendy B, Burris TP. Antihyperlipidemic Activity of Gut-Restricted LXR Inverse Agonists. ACS Chem Biol 2022;17:1143-54. [PMID: 35417135 DOI: 10.1021/acschembio.2c00057] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
6 Gui Y, Zheng H, Cao RY. Foam Cells in Atherosclerosis: Novel Insights Into Its Origins, Consequences, and Molecular Mechanisms. Front Cardiovasc Med 2022;9:845942. [PMID: 35498045 DOI: 10.3389/fcvm.2022.845942] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Lewandowski CT, Laham MS, Thatcher GRJ. Remembering your A, B, C's: Alzheimer's disease and ABCA1. Acta Pharm Sin B 2022;12:995-1018. [PMID: 35530134 DOI: 10.1016/j.apsb.2022.01.011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
8 Lianto P, Hutchinson SA, Moore JB, Hughes TA, Thorne JL. Characterization and prognostic value of LXR splice variants in triple-negative breast cancer. iScience 2021;24:103212. [PMID: 34755086 DOI: 10.1016/j.isci.2021.103212] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
9 Zanotti I, Potì F, Cuchel M. HDL and reverse cholesterol transport in humans and animals: Lessons from pre-clinical models and clinical studies. Biochim Biophys Acta Mol Cell Biol Lipids 2022;1867:159065. [PMID: 34637925 DOI: 10.1016/j.bbalip.2021.159065] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
10 Nishimura Y, Yamakawa D, Uchida K, Shiromizu T, Watanabe M, Inagaki M. Primary cilia and lipid raft dynamics. Open Biol 2021;11:210130. [PMID: 34428960 DOI: 10.1098/rsob.210130] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
11 Nixon M, Andrew R. Oxysterols as therapeutic targets. Br J Pharmacol 2021;178:3085-8. [PMID: 34278569 DOI: 10.1111/bph.15577] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Lianto P, Moore JB, Hughes TA, Thorne JL. Comprehensive profiling of liver x receptor splicing in triple negative breast cancer reveals existence of novel splice variants that are prognostic for survival.. [DOI: 10.1101/2021.06.09.445161] [Reference Citation Analysis]